Clinical Trial Update: A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients [Phase 1, Phase 2]

View source ↗

Summary

This is a clinical trial update describing a Phase 1/2 study of Roginolisib (IOA-244) in combination with Dostarlimab, with or without Docetaxel, for metastatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Dostarlimab (dostarlimab)
• Roginolisib (IOA-244) (roginolisib)

Snippet

Sponsor: iOnctura | Conditions: Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING